Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: Correlation with pulmonary dose-volume histogram parameters

被引:131
作者
Lee, HK
Vaporciyan, AA
Cox, JD
Tucker, SL
Putnam, JB
Ajani, JA
Liao, ZX
Swisher, SG
Roth, JA
Smythe, WR
Walsh, GL
Mohan, R
Liu, HH
Mooring, D
Komaki, R
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Oncol & Digest Dis, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 57卷 / 05期
关键词
pulmonary complications; preoperative chemoradiation; esophageal cancer; dose-volume histogram; postoperative morbidity;
D O I
10.1016/S0360-3016(03)01373-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To clarify the relationship between the percentage of lung receiving low radiation doses with concurrent chemotherapy and the occurrence of postoperative pulmonary complications in the treatment of esophageal carcinoma. Methods: From 117 patients who underwent preoperative chemoradiation for esophageal cancer at our institution between 1998 and 2002, we selected 61 patients for whom complete pulmonary dose-volume histogram (DVH) data were available and analyzed the incidence of pneumonia and acute respiratory distress syndrome (ARDS) in this group. All patients received concurrent chemoradiation therapy, and 39 patients also received induction chemotherapy before concurrent chemoradiation. The median age was 62 years, and the median radiotherapy dose was 45 Gy. The percentage of lung volume receiving at least 10 Gy (V10), 15 Gy (V15), and 20 Gy (V20) were recorded from each pulmonary DVH. Results: Eleven (18%) of the 61 patients had pulmonary complications, 2 of whom died after progression of pneumonia. Pulmonary complications were noted more often (35% vs. 8%, p = 0.014) when the pulmonary V10 was greater than or equal to40% vs. <40% and when the V15 was ≥30% vs. <30% (33% vs. 10%, p = 0.036). An apparent increase in pulmonary complication rate when V20 was greater than or equal to20% vs. <20% (32% vs. 10%, p = 0.079) was not significant. None of the other factors analyzed (surgical procedure, tumor location, use of induction chemotherapy, use of concurrent taxane-based chemoradiation, or smoking history) was associated with the occurrence of pulmonary complications. The median hospital stay was 17 days for patients who had pulmonary complications vs. 12 days for patients who did not (p = 0.08). Conclusion: The use of multimodality therapy may require minimization of lung volume irradiation to levels lower than previously expected. Radiotherapy techniques that decrease the volume of lung receiving low radiation doses may significantly reduce the risk of this potentially life-threatening complication. © 2003 Elsevier Inc.
引用
收藏
页码:1317 / 1322
页数:6
相关论文
共 37 条
[1]  
Adelstein DJ, 1997, CANCER-AM CANCER SOC, V80, P1011
[2]  
*AJCC, 2002, AJCC CANC STAG HDB
[3]  
[Anonymous], 1989, AM REV RESPIR DIS, V139, P1058
[4]   Plasma transforming growth factor β1 as a predictor of radiation pneumonitis [J].
Anscher, MS ;
Kong, FM ;
Andrews, K ;
Clough, R ;
Marks, LB ;
Bentel, G ;
Jirtle, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05) :1029-1035
[5]   THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
COCHIN, B ;
LANKEN, PN ;
LEEPER, KV ;
MARINI, J ;
MURRAY, JF ;
OPPENHEIMER, L ;
PESENTI, A ;
REID, L ;
RINALDO, J ;
VILLAR, J ;
VANASBECK, BS ;
DHAINAUT, JF ;
MANCEBO, J ;
MATTHAY, M ;
MEYRICK, B ;
PAYEN, D ;
PERRET, C ;
FOWLER, AA ;
SCHALLER, MD ;
HUDSON, LD ;
HYERS, T ;
KNAUS, W ;
MATTHAY, R ;
PINSKY, M ;
BONE, RC ;
BOSKEN, C ;
JOHANSON, WG ;
LEWANDOWSKI, K ;
REPINE, J ;
RODRIGUEZROISIN, R ;
ROUSSOS, C ;
ANTONELLI, MA ;
BELOUCIF, S ;
BIHARI, D ;
BURCHARDI, H ;
LEMAIRE, F ;
MONTRAVERS, P ;
PETTY, TL ;
ROBOTHAM, J ;
ZAPOL, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :818-824
[6]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[7]  
Coia LR, 1999, CANCER, V85, P2499, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2499::AID-CNCR2>3.0.CO
[8]  
2-T
[9]   Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].
Cooper, JS ;
Guo, MD ;
Herskovic, A ;
Macdonald, JS ;
Martenson, JA ;
Al-Sarraf, M ;
Byhardt, R ;
Russell, AH ;
Beitler, JJ ;
Spencer, S ;
Asbell, SO ;
Graham, MV ;
Leichman, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627
[10]   MULTIPLE ORGAN FAILURE - PATHOPHYSIOLOGY AND POTENTIAL FUTURE THERAPY [J].
DEITCH, EA .
ANNALS OF SURGERY, 1992, 216 (02) :117-134